Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1189

—

46002601-1ec4-521c-bfb3-9aade2f9bff7

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.669
  • ANGIOGENESIS+0.549
  • IL6_JAK_STAT3_SIGNALING+0.540
  • INFLAMMATORY_RESPONSE+0.526
  • ALLOGRAFT_REJECTION+0.459
  • P53_PATHWAY+0.417
  • OXIDATIVE_PHOSPHORYLATION+0.400
  • KRAS_SIGNALING_UP+0.388
  • COMPLEMENT+0.358
  • APOPTOSIS+0.352

Top 10 suppressed

  • MITOTIC_SPINDLE-0.299
  • E2F_TARGETS-0.274
  • SPERMATOGENESIS-0.208
  • APICAL_SURFACE-0.198
  • G2M_CHECKPOINT-0.193
  • HEDGEHOG_SIGNALING-0.136
  • WNT_BETA_CATENIN_SIGNALING-0.086
  • DNA_REPAIR-0.042
  • PEROXISOME-0.034
  • MYOGENESIS-0.026

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG919
mng-umap@100
——0.884
2MNG878
mng-umap@100
——0.880
3SJEPD030600_D1.RNA-Seq
medullo-epn-umap@date-based
EPNSupratentorial EPN0.875
4SJEPD031285_D1.RNA-Seq
medullo-epn-umap@date-based
EPNEPN Tumor0.872
553D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D
brain-umap@2
——0.870
6MNG202
mng-umap@100
——0.869
75B9D33F5-1B4F-4C06-A73A-CC723C1EF409
brain-umap@2
——0.865
817-026K4_Bladder
bladder-landscape@3
——0.861
9MNG1212
mng-umap@100
——0.861
10BS_8RHPJ740
medullo-epn-umap@date-based
EPNEPN Tumor0.859

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 40 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.669Inavolisib— uncovered
ANGIOGENESIS0.549Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.540Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.526Idelalisib— uncovered
ALLOGRAFT_REJECTION0.459Idelalisib— uncovered
P53_PATHWAY0.417Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.400Remibrutinib— uncovered
KRAS_SIGNALING_UP0.388Inavolisib— uncovered
COMPLEMENT0.358Inavolisib— uncovered
APOPTOSIS0.352Idelalisib— uncovered
IL2_STAT5_SIGNALING0.349Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.348Inavolisib— uncovered
HYPOXIA0.336Idelalisib— uncovered
TGF_BETA_SIGNALING0.331Inavolisib— uncovered
PROTEIN_SECRETION0.322Remibrutinib— uncovered
COAGULATION0.307Binimetinib— uncovered
ADIPOGENESIS0.302Inavolisib— uncovered
MYC_TARGETS_V10.301Inavolisib— uncovered
MTORC1_SIGNALING0.300Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.296Idelalisib— uncovered